785 related articles for article (PubMed ID: 16323121)
21. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.
Jones RN
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S13-24. PubMed ID: 16323115
[TBL] [Abstract][Full Text] [Related]
22. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G; Moellering RC
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
[TBL] [Abstract][Full Text] [Related]
23. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis.
Fernández Guerrero ML; de Górgolas M
J Antimicrob Chemother; 2006 Nov; 58(5):1066-9. PubMed ID: 16931540
[TBL] [Abstract][Full Text] [Related]
24. Fatal bacteraemia and infective endocarditis due to meticillin-resistant Staphylococcus aureus (MRSA) with rapid emergence of rifampicin resistance during vancomycin/rifampicin combination treatment.
Liu WL; Hung YL; Lin SH; Lee PI; Hsueh PR
Int J Antimicrob Agents; 2010 Jun; 35(6):615-6. PubMed ID: 20236804
[No Abstract] [Full Text] [Related]
25. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Soriano A; Marco F; Martínez JA; Pisos E; Almela M; Dimova VP; Alamo D; Ortega M; Lopez J; Mensa J
Clin Infect Dis; 2008 Jan; 46(2):193-200. PubMed ID: 18171250
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
Tsaganos T; Skiadas I; Koutoukas P; Adamis T; Baxevanos N; Tzepi I; Pelekanou A; Giamarellos-Bourboulis EJ; Giamarellou H; Kanellakopoulou K
J Antimicrob Chemother; 2008 Aug; 62(2):381-3. PubMed ID: 18445576
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
[TBL] [Abstract][Full Text] [Related]
28. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.
Boucher HW; Sakoulas G
Clin Infect Dis; 2007 Sep; 45(5):601-8. PubMed ID: 17682996
[TBL] [Abstract][Full Text] [Related]
29. [Demethyl-vancomycin in treatment of resistant staphylococcal infections. A clinical evaluation].
Zhu F
Zhonghua Yi Xue Za Zhi; 1992 Sep; 72(9):562-4, 575. PubMed ID: 1338524
[TBL] [Abstract][Full Text] [Related]
30. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy.
Falcone M; Russo A; Pompeo ME; Vena A; Marruncheddu L; Ciccaglioni A; Grossi P; Mancini C; Novelli A; Stefani S; Venditti M
Int J Antimicrob Agents; 2012 Jan; 39(1):64-8. PubMed ID: 22047703
[TBL] [Abstract][Full Text] [Related]
31. [Infective endocarditis due to high level aminoglycoside resistant Enterococcus faecalis and methicillin resistant coagulase-negative staphylococci presenting with rheumatic manifestations].
Pişkin N; Akduman D; Aydemir H; Celebi G; Oztoprak N; Aktaş E
Mikrobiyol Bul; 2008 Jul; 42(3):509-14. PubMed ID: 18822897
[TBL] [Abstract][Full Text] [Related]
32. Influence of in vitro susceptibility phenotype against thrombin-induced platelet microbicidal protein on treatment and prophylaxis outcomes of experimental Staphylococcus aureus endocarditis.
Dhawan VK; Yeaman MR; Bayer AS
J Infect Dis; 1999 Nov; 180(5):1561-8. PubMed ID: 10515816
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with daptomycin: bacteraemia and endocarditis.
Levine DP
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
[TBL] [Abstract][Full Text] [Related]
34. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy.
Awad SS; Elhabash SI; Lee L; Farrow B; Berger DH
Am J Surg; 2007 Nov; 194(5):606-10. PubMed ID: 17936421
[TBL] [Abstract][Full Text] [Related]
35. Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus.
Rayner C; Munckhof WJ
Intern Med J; 2005 Dec; 35 Suppl 2():S3-16. PubMed ID: 16271060
[TBL] [Abstract][Full Text] [Related]
36. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care.
Tverdek FP; Crank CW; Segreti J
Crit Care Clin; 2008 Apr; 24(2):249-60, vii-viii. PubMed ID: 18361944
[TBL] [Abstract][Full Text] [Related]
37. Treatment of severe infections caused by Staphylococcus aureus: a change in the vancomycin paradigm?
Aranha Camargo LF
Shock; 2008 Oct; 30 Suppl 1():67-9. PubMed ID: 18704006
[TBL] [Abstract][Full Text] [Related]
38. A general survey of antibiotic treatment of staphylococcal septicaemia and endocarditis.
Watanakunakorn C
Scand J Infect Dis Suppl; 1983; 41():151-7. PubMed ID: 6589752
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children.
Marcinak JF; Frank AL
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):91-100. PubMed ID: 16441212
[TBL] [Abstract][Full Text] [Related]
40. Staphylococcus aureus bacteremia and endocarditis.
Chang FY
J Microbiol Immunol Infect; 2000 Jun; 33(2):63-8. PubMed ID: 10917874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
